Previous Close | 1.2000 |
Open | 1.1433 |
Bid | 0.0000 x 29200 |
Ask | 0.0000 x 2200 |
Day's Range | 1.0700 - 1.4300 |
52 Week Range | 0.5000 - 10.2000 |
Volume | 8,630,467 |
Avg. Volume | 3,914,569 |
Market Cap | 26.676M |
Beta (5Y Monthly) | 1.90 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.8220 |
Earnings Date | Aug 11, 2020 - Aug 17, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the closing of its previously announced public offering of 18,750,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof), together with warrants to purchase up to 18,750,000 shares of common stock at a combined effective price to the public of $0.80 per share (or pre-funded warrant) and associated warrant. The gross proceeds from this offering were $15.0 million, before deducting the placement agent fees and offering expenses payable by InVivo Therapeutics.
InVivo Therapeutics Holdings Corp. (NVIV) today announced the pricing of a public offering of 18,750,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof), together with warrants to purchase up to 18,750,000 shares of common stock at a combined effective price to the public of $ 0.80 per share (or pre-funded warrant) and associated warrant. The gross proceeds from this offering are expected to be approximately $15.0 million, before deducting the placement agent fees and offering expenses payable by InVivo Therapeutics.